Hemostemix Inc. (CVE:HEM – Get Free Report) was up 17.5% during trading on Friday . The company traded as high as C$0.24 and last traded at C$0.24. Approximately 720,526 shares changed hands during mid-day trading, an increase of 35% from the average daily volume of 533,339 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The stock has a market capitalization of C$20.47 million, a price-to-earnings ratio of -11.75 and a beta of 0.20. The business has a 50-day moving average of C$0.09 and a 200-day moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- When to Sell a Stock for Profit or Loss
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Energy and Oil Stocks Explained
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
